Literature DB >> 11273770

An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.

A I Kuzmin1, O Galenko, R C Eisensmith.   

Abstract

Immune responses against E1-deleted adenovirus vectors and/or their transgene products result in the rapid elimination of vector-transduced cells and the generation of neutralizing antibodies. Different strategies of immunomodulation to stabilize transgene expression at therapeutic levels and to permit productive vector readministration have been examined. Our previous studies have shown that depletion of macrophages from spleen and liver decreases hepatic inflammation, significantly prolongs transgene expression, and delays the onset of humoral immune responses after systemic administration of an E1-deleted adenovirus vector. In the present study, we have examined the effects of macrophage depletion in combination with temporary blockade of CD40 ligation on E1-deleted adenovirus vector-mediated gene transfer. Alone, each of these treatments significantly inhibited the humoral immune response against the transgene product and prolonged its expression. Together, these treatments completely stabilized transgene expression and inhibited the production of neutralizing anti-adenovirus antibodies, permitting successful vector readministration. Animals rendered immunologically unresponsive to vector and transgene antigens regained their ability to mount productive immune responses against the vector after recovery of immune function, but remained unresponsive to the transgene product. These experiments demonstrate that this treatment is transient and antigen-specific.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273770     DOI: 10.1006/mthe.2000.0258

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  8 in total

1.  Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Authors:  Naoya Koizumi; Hiroyuki Mizuguchi; Fuminori Sakurai; Teruhide Yamaguchi; Yoshiteru Watanabe; Takao Hayakawa
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 2.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

3.  In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system.

Authors:  E M Torres; C Monville; P R Lowenstein; M G Castro; S B Dunnett
Journal:  Brain Res Mol Brain Res       Date:  2005-04-18

4.  Co-expression of sCD40LIg and CTLA4Ig mediated by adenovirus prolonged mouse skin allograft survival.

Authors:  Zhao-lun Li; Pu-xun Tian; Wu-jun Xue; Jun Wu
Journal:  J Zhejiang Univ Sci B       Date:  2006-06       Impact factor: 3.066

5.  Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.

Authors:  Eric A Weaver
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

6.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

7.  Mouse adenovirus type 1 infection of macrophages.

Authors:  Shanna L Ashley; Amanda R Welton; Kirsten M Harwood; Nico Van Rooijen; Katherine R Spindler
Journal:  Virology       Date:  2009-06-21       Impact factor: 3.616

8.  Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors.

Authors:  B van Etten; A M M Eggermont; G Ambagtsheer; S T van Tiel; T L M ten Hagen
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.